Exosomes in Rectal Cancer

Description

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.

Conditions

Rectal Cancer

Study Overview

Study Details

Study overview

The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy. Compare rates of exosomal expression before during and after chemoradiation therapy with pathologic response rates at the time of APR or LAR. The researchers will also examine the functionality of these exosomes in malignant colonic organoids and mouse models of colorectal cancer.

Exosomal As Correlative Biomarker in Clinical Outcomes in Patients Undergoing Neoadjuvant Chemoradiation Therapy for Rectal Cancer

Exosomes in Rectal Cancer

Condition
Rectal Cancer
Intervention / Treatment

-

Contacts and Locations

Kansas City

University of Kansas Medical Center/ Cancer Center, Kansas City, Kansas, United States, 66190

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male and Female Patients aged 18 and older
  • * histologically proven diagnosis of rectal adenocarcinoma
  • * will be receiving neoadjuvant chemoradiation therapy prior to a planned definitive surgical resection
  • * Age less than 18.
  • * Patients who are unable or unwilling to undergo definitive surgery.
  • * Patients with a prior history of pelvic external beam radiation, brachytherapy, or chemotherapy.
  • * Patients with a prior history of cancer (excluding non-melanoma skin cancers).
  • * Patients who are immunocompromised.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Kansas Medical Center,

Andrew Hoover, MD, PRINCIPAL_INVESTIGATOR, The University of Kansas Medical Center

Study Record Dates

2026-02-01